Gavriilaki, Eleni and Sakellari, Ioanna and Labopin, Myriam and Bornhaeuser, Martin and Hamladji, Rose-Marie and Casper, Jochen and Edinger, Matthias and Zak, Pavel and Yakoub-Agha, Ibrahim and Ciceri, Fabio and Schroeder, Thomas and Zuckerman, Tsila and Kobbe, Guido and Yeshurun, Moshe and Narni, Franco and Finke, Juergen and Diez-Martin, Jose Luiz and Berceanu, Ana and Hilgendorf, Inken and Verbeek, Mareike and Olivieri, Attilio and Savani, Bipin and Spyridonidis, Alexandros and Nagler, Arnon and Mohty, Mohamad (2023) Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP). BONE MARROW TRANSPLANTATION, 58 (10). pp. 1084-1088. ISSN 0268-3369, 1476-5365
Full text not available from this repository. (Request a copy)Abstract
We compared FT14 (fludarabine 150-160 mg/m(2), treosulfan 42 g/m(2)) versus FB4 (fludarabine 150-160 mg/m(2), busulfan 12.8 mg/kg) in acute myeloid leukemia (AML) transplanted at primary refractory/relapsed disease. We retrospectively studied: (a) adults diagnosed with AML, (b) recipients of first allogeneic hematopoietic stem cell transplantation (HSCT) from unrelated/sibling donor (2010-2020), (c) HSCT with primary refractory/relapsed disease, (d) conditioning regimen with FT14 or FB4. We studied 346 patients, 113 transplanted with FT14, and 233 with F & UBeta;4. FT14 patients were significantly older, more frequently had an unrelated donor and had received a lower dose of fludarabine. Cumulative incidence (CI) of acute graft-versus-host disease (GVHD) grade III-IV and extensive chronic GVHD was similar. With a median follow-up of 28.7 months, 2-year CI of relapse was 43.4% in FT14 versus 53.2% in FB4, while non-relapse mortality (NRM) was respectively 20.8% versus 22.6%. This led to 2-year leukemia-free survival (LFS) of 35.8% for FT14 versus 24.2% in FB4, and overall survival (OS) of 44.4% versus 34%. Adverse cytogenetics and conditioning regimen independently predicted CI of relapse. Furthermore, conditioning regimen was the only independent predictor of LFS, OS, and GVHD-free/relapse-free survival. Therefore, our real-world multicenter study suggests that FT14 is associated with better outcomes in primary refractory/relapsed AML.
| Item Type: | Article |
|---|---|
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 13 Mar 2024 08:03 |
| Last Modified: | 13 Mar 2024 08:03 |
| URI: | https://pred.uni-regensburg.de/id/eprint/60849 |
Actions (login required)
 |
View Item |
